Upregulated KLK10 inhibits esophageal cancer proliferation and enhances cisplatin sensitivity in vitro

Li,Lei; Xu,Nan; Fan,Ning; Meng,Qingchun; Luo,Wenchao; Lv,Lijia; Ma,Wei; Liu,Xiaoyu; Liu,Lu; Xu,Fei; Wang,Huaxin; Mao,Weifeng; Li,Yan

doi:10.3892/or.2015.4211

Upregulated KLK10 inhibits esophageal cancer proliferation and enhances cisplatin sensitivity in vitro

Authors:
- Lei Li
- Nan Xu
- Ning Fan
- Qingchun Meng
- Wenchao Luo
- Lijia Lv
- Wei Ma
- Xiaoyu Liu
- Lu Liu
- Fei Xu
- Huaxin Wang
- Weifeng Mao
- Yan Li
View Affiliations

Affiliations: College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Thoracic Surgery, Anshan City Cancer Hospital, Anshan, Liaoning 114000, P.R. China
Published online on: August 20, 2015 https://doi.org/10.3892/or.2015.4211
Pages: 2325-2332

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The kallikrein-related peptidase 10 (KLK10) gene has tumor-suppressive function in various types of human cancer. However, previous studies showed that KLK10 also acts as an oncogene and is upregulated in gastrointestinal tumors. The role of KLK10 in human esophageal cancer (EC) remains unclear. In the present study, the expression of KLK10 in human esophageal and non-esophageal cancer tissues was investigated by immunohistochemistry. Quantitative RT-PCR and western blot analysis were utilized to detect KLK10 mRNA and protein expression in human esophageal cancer cell lines (TE-1 and Eca-109). Small interference RNA was utilized to specifically knockdown KLK10 expression in Eca-109 and TE-1 cells. Cell proliferation, cell cycle analysis as well as CDDP-dependent apoptosis were determined using a CCK-8 assay and flow cytometry. The results showed that, KLK10 was positive in 67 out of 83 (80.72%) human EC and positive in 3 out of 11 (27.27%) normal tissues (P=0.001). The present study indicated that KLK10 potentially plays a crucial role in Eca-109 cell growth. Additionally, the downregulation of KLK10 induced S-phase arrest and promoted cisplatin-induced apoptosis. The resutls of the present study suggested that KLK10 is a promising novel marker for the diagnostic and therapeutic target of esophageal cancer.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2014. View Article : Google Scholar : PubMed/NCBI
2	Dawsey SP, Tonui S, Parker RK, Fitzwater JW, Dawsey SM, White RE and Abnet CC: Esophageal cancer in young people: A case series of 109 cases and review of the literature. PLoS One. 5:e140802010. View Article : Google Scholar : PubMed/NCBI
3	Zhang HY, Spechler SJ and Souza RF: Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett. 275:170–177. 2009. View Article : Google Scholar :
4	Hong J, Peng D, Chen Z, Sehdev V and Belkhiri A: ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res. 73:331–340. 2013. View Article : Google Scholar
5	Grünberger B, Raderer M, Schmidinger M and Hejna M: Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res. 27(4C): 2705–2714. 2007.PubMed/NCBI
6	Lin C, Song L, Gong H, Liu A, Lin X, Wu J, Li M and Li J: Nkx2-8 downregulation promotes angiogenesis and activates NF-κB in esophageal cancer. Cancer Res. 73:3638–3648. 2013. View Article : Google Scholar : PubMed/NCBI
7	Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D and Foidart JM: Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol. 57:577–584. 2004. View Article : Google Scholar : PubMed/NCBI
8	Borgoño CA and Diamandis EP: The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 4:876–890. 2004. View Article : Google Scholar : PubMed/NCBI
9	Lawrence MG, Lai J and Clements JA: Kallikreins on steroids: Structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev. 31:407–446. 2010. View Article : Google Scholar : PubMed/NCBI
10	Luo LY, Grass L, Howarth DJ, Thibault P, Ong H and Diamandis EP: Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem. 47:237–246. 2001.PubMed/NCBI
11	Talieri M, Alexopoulou DK, Scorilas A, Kypraios D, Arnogiannaki N, Devetzi M, Patsavela M and Xynopoulos D: Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol. 32:737–744. 2011. View Article : Google Scholar : PubMed/NCBI
12	Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, Stephan C, Jung K and Diamandis EP: Intron retention: A common splicing event within the human kallikrein gene family. Clin Chem. 51:506–515. 2005. View Article : Google Scholar : PubMed/NCBI
13	Liu XL, Wazer DE, Watanabe K and Band V: Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 56:3371–3379. 1996.PubMed/NCBI
14	Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D and Diamandis EP: Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 26:324–336. 2005. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Song H, Miao Y, Wang R and Chen L: Frequent transcriptional inactivation of kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 101:934–940. 2010. View Article : Google Scholar : PubMed/NCBI
16	White NM, Bui A, Mejia-Guerrero S, Chao J, Soosaipillai A, Youssef Y, Mankaruos M, Honey RJ, Stewart R, Pace KT, et al: Dysregulation of kallikrein-related peptidases in renal cell carcinoma: Potential targets of miRNAs. Biol Chem. 391:411–423. 2010. View Article : Google Scholar : PubMed/NCBI
17	Treeck O, Schüler S, Häring J, Skrzypczak M, Lattrich C and Ortmann O: icb-1 gene counteracts growth of ovarian cancer cell lines. Cancer Lett. 335:441–446. 2013. View Article : Google Scholar : PubMed/NCBI
18	Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A and Pecorelli S: Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am J Obstet Gynecol. 194:1296–1302. 2006. View Article : Google Scholar : PubMed/NCBI
19	Rückert F, Hennig M, Petraki CD, Wehrum D, Distler M, Denz A, Schröder M, Dawelbait G, Kalthoff H, Saeger HD, et al: Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer. 99:1484–1492. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wang YY, Lin YC, Hung HC, Tien WY and Shieh TY: Polymorphisms in kallikrein7 and 10 genes and oral cancer risks in Taiwan betel quid chewers and smokers. Oral Dis. 19:824–832. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pettus JR, Johnson JJ, Shi Z, Davis JW, Koblinski J, Ghosh S, Liu Y, Ravosa MJ, Frazier S and Stack MS: Multiple kallikrein (KLK 5,7,8, and 10) expression in squamous cell carcinoma of the oral cavity. Histol Histopathol. 24:197–207. 2009.
22	Luo LY, Grass L and Diamandis EP: Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin Chim Acta. 337:115–126. 2003. View Article : Google Scholar : PubMed/NCBI
23	Li B, Goyal J, Dhar S, Dimri G, Evron E, Sukumar S, Wazer DE and Band V: CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 61:8014–8021. 2001.PubMed/NCBI
24	Bin L, Kim BE, Hall CF, Leach SM and Leung DY: Inhibition of transcription factor specificity protein 1 alters the gene expression profile of keratinocytes leading to upregulation of kallikrein-related peptidases and thymic stromal lymphopoietin. J Invest Dermatol. 131:2213–2222. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hao XP, Pretlow TG, Rao JS and Pretlow TP: Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res. 61:8085–8088. 2001.PubMed/NCBI
26	Ling S, Feng T, Ke Q, Fan N, Li L, Li Z, Dong C, Wang C, Xu F, Li Y, et al: Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep. 31:2611–2618. 2014.PubMed/NCBI
27	Li X, Suo J, Shao S, Xue L, Chen W, Dong L, Shi J, Fu M, Lu N, Zhan Q, et al: Overexpression of OLC1 promotes tumorigenesis of human esophageal squamous cell carcinoma. PLoS One. 9:e909582014. View Article : Google Scholar : PubMed/NCBI
28	White NM, Chow TF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, Mankaruous M, Gabril M, Girgis A and Yousef GM: Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer. 102:1244–1253. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jiao X, Lu HJ, Zhai MM, Tan ZJ, Zhi HN, Liu XM, Liu CH and Zhang DP: Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer. World J Gastroenterol. 19:9425–9431. 2013. View Article : Google Scholar
30	Kolin DL, Sy K, Rotondo F, Bassily MN, Kovacs K, Brezden-Masley C, Streutker CJ and Yousef GM: Prognostic significance of human tissue kallikrein-related peptidases 6 and 10 in gastric cancer. Biol Chem. 395:1087–1093. 2014. View Article : Google Scholar : PubMed/NCBI
31	Alexopoulou DK, Papadopoulos IN and Scorilas A: Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clin Biochem. 46:1453–1461. 2013. View Article : Google Scholar : PubMed/NCBI
32	Wang BY, Goan YG, Hsu PK, Hsu WH and Wu YC: Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 91:887–893. 2011. View Article : Google Scholar : PubMed/NCBI
33	Wang BY, Liu CY, Lin CH, Hsu PK, Hsu WH, Wu YC and Cheng CY: Endoscopic tumor length is an independent prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol. 19:2149–2158. 2012. View Article : Google Scholar : PubMed/NCBI
34	Eastman A: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem. 91:223–231. 2004. View Article : Google Scholar : PubMed/NCBI